Hemodiafiltration & High-Flux

The contract between this chapter and the reader.

1. 1. Define hemodiafiltration and how it differs from hemodialysis and hemofiltration.
2. 2. Explain convection and why it clears middle molecules better than diffusion.
3. 3. Describe online HDF and its ultrapure-water requirement.
4. 4. Define convection volume as the dose of HDF.
5. 5. Compare pre- and post-dilution and their trade-offs.
6. 6. Distinguish high-flux HD from hemodiafiltration.
7. 7. Appraise the evidence on HDF survival and its convection-volume dependence.
8. 8. Identify the practical requirements to deliver high-volume HDF.
9. 9. Relate middle-molecule clearance to dialysis-related amyloidosis.

A sixty-second reading. Each bullet stands alone.

• Hemodiafiltration combines the diffusion of HD with substantial convection in one treatment, using a high-flux membrane and large-volume replacement fluid.
• Convection clears middle molecules — such as β₂-microglobulin — far better than diffusion.
• Online HDF makes its replacement fluid from ultrapure dialysate, so it requires ultrapure water.
• The dose of HDF is the convection volume; higher volumes clear more middle molecules.
• Post-dilution is more efficient but limited by filtration fraction and clotting; pre-dilution allows higher volumes but dilutes the blood.
• High-flux HD allows some convective transport through the membrane, but far less than formal HDF.
• High-flux versus low-flux HD shows no overall survival difference, so high-flux alone is a modest gain.
• High-volume post-dilution online HDF is associated with a survival benefit over conventional HD, dependent on achieving a high convection volume.
• Delivering high-volume HDF needs good vascular access and blood flow, ultrapure dialysate, and a high-flux dialyzer.
• The filtration fraction is monitored to avoid clotting at high convection volumes.
• β₂-microglobulin accumulation causes dialysis-related amyloidosis; HDF and high-flux lower it.
• HDF is not universally available and carries cost and infrastructure demands.

The medical core. An expert should agree HDF and high-flux therapy are fully covered here.

Why it matters at the bedside

Conventional dialysis is good at clearing small solutes and poor at the larger ones that accumulate over years. Hemodiafiltration adds convection to reach those middle molecules, and — when delivered at high volume — is the one modality change with a credible survival signal over standard HD. The catch is in that phrase: the benefit lives in the dose.

What HDF is

• Hemodiafiltration runs diffusion and substantial convection together in a single treatment, across a high-flux membrane, with large-volume replacement fluid to make up the fluid removed by convection. It sits between hemodialysis (diffusion-dominant) and hemofiltration (convection-only), combining the strengths of both.

Convection and middle molecules

• Diffusion clears small solutes well but middle molecules poorly, because larger molecules diffuse slowly. Convection — solvent drag, where solutes are swept along with ultrafiltered water — carries middle molecules across far more effectively. HDF exploits this to clear β₂-microglobulin and other larger uraemic toxins that conventional HD leaves behind.

Online HDF and ultrapure water

• Modern HDF is online: the large volume of replacement fluid is produced in real time from ultrapure dialysate. Because that fluid is infused directly into the patient's blood, the water and dialysate must be ultrapure — making water treatment (its own chapter) a non-negotiable prerequisite for HDF.

Convection volume: the dose

• The defining variable of HDF is the convection volume — the total volume of fluid convected (and replaced) per session. It is the dose: higher convection volumes clear more middle molecules, and the survival signal in the trials appears only when a high volume (broadly, a high post-dilution target per session) is achieved. Low-volume HDF is HDF in name only.

Pre- versus post-dilution

• Replacement fluid given after the filter (post-dilution) is the most efficient per litre but is limited by the filtration fraction — push it too far and the blood hemoconcentrates and the filter clots. Pre-dilution (before the filter) permits much higher volumes by diluting the blood, at the cost of efficiency per litre. Reaching a high convection volume safely is a balance between the two, and it demands good blood flow.

High-flux HD versus HDF

• A high-flux membrane in conventional HD permits some convective transport through internal filtration and backfiltration, giving modest middle-molecule clearance — but far less than formal HDF with its replacement fluid. High-flux HD is a step up from low-flux, not a substitute for high-volume HDF.

The evidence: survival and convection volume

• Two strands matter. First, high-flux versus low-flux HD showed no overall survival difference, so the membrane alone is a modest gain. Second, randomised and pooled evidence indicates that high-volume post-dilution online HDF is associated with better survival than conventional HD — but the benefit is convection-volume dependent, concentrated in patients who actually reach a high dose. The lesson mirrors the prescription chapter: the dose, achieved, is what matters.

Delivering high-volume HDF

• Reaching the target convection volume is a practical challenge: it needs a high blood-flow rate and therefore good vascular access, ultrapure dialysate, a high-flux dialyzer, and attention to the filtration fraction. When the volume falls short, the first thing to optimise is access and blood flow — not to accept a low-dose treatment and call it HDF.

Middle molecules and amyloidosis

• β₂-microglobulin accumulates over years of dialysis and deposits as amyloid, causing carpal tunnel syndrome and a destructive arthropathy. HDF and high-flux membranes lower β₂-microglobulin levels; the clinical amyloid benefit is real but slow, accruing over long-term treatment.

Evidence base

• The superiority of convection for middle molecules rests on physiology and clearance studies; the survival association of high-volume HDF rests on randomised trials and individual-patient pooled analyses, conditioned on convection volume; and the neutrality of high-flux versus low-flux rests on a large randomised trial.

Five fully-built tables.

Table A — HD versus HF versus HDF

Table B — Convection volume (the dose)

Table C — Pre- versus post-dilution

Table D — Requirements for HDF

Table E — High-flux HD versus high-volume HDF

Visualise & Map

Causal chains, each ending in a named action.

Chain 1 — Convection reaches the middle molecules

Ultrafiltration → solvent drag → middle molecules swept across the membrane → better middle-molecule clearance → ACTION: use HDF when middle-molecule clearance is the goal.

Chain 2 — Volume is the dose

Higher convection volume → more middle-molecule removal → the survival signal appears → ACTION: target a high convection volume, not just ‘HDF’.

Chain 3 — The post-dilution ceiling

High post-dilution volume → haemoconcentration at the filter → clotting limits the dose → ACTION: balance pre- and post-dilution and secure good blood flow.

Chain 4 — The online requirement

Replacement fluid made online and infused → must be ultrapure → contamination would enter the blood → ACTION: ensure ultrapure water and dialysate before HDF.

Chain 5 — β₂-microglobulin and amyloid

Years of poor middle-molecule clearance → β₂-microglobulin accumulates → amyloid deposition (carpal tunnel, arthropathy) → ACTION: HDF/high-flux to lower β₂-microglobulin over the long term.

Numbered rules. These numbers are the cross-reference handle for the cases and flowcharts.

Clinical Reasoning

Four cases. Each stops you at a decision before it answers it.

Every mechanism from Level 3 earns a bedside consequence and an action.

Exhaustive. Every threshold and rule in the chapter is here.

Safety & Evidence

Panel A — Red flags

Panel B — NEVER DO

Anti-patterns clinicians fall into. Each becomes a Level 22 distractor.

The grade reflects strength of evidence, not importance.

Patient Decisions

Outcomes as natural frequencies. Figures are representative; the direction of effect is given where precise numbers are uncertain.

Apply & Test

Copy-paste chart notes that map to the real decisions in this chapter.

Template 1 — HDF prescription note

• Water/dialysate: ultrapure confirmed: yes/no.
• Dialyzer: high-flux; surface area ___.
• Mode: post-dilution / pre-dilution / mixed; rationale ___.
• Convection volume target: ___ L/session; achieved: ___ L.
• Blood flow (Qb) ___; filtration fraction within limits: yes/no.

Template 2 — Convection-volume troubleshooting note

• Target vs achieved convection volume: ___.
• Limiting factor: filtration fraction / blood flow / access.
• Adjustment: shift pre/post-dilution / optimise access / raise Qb.
• Re-checked achieved volume: ___.
• If still sub-target: best achievable dose accepted / plan ___.

Pre-rounds compression. Rules only.

Active recall. At least one card per objective.

Micro-teaching for rounds. Two scenarios, five steps each.

Metacognition anchored to this chapter's tensions. No answers provided.

1. 1. HDF's benefit lives entirely in a dose many units struggle to reach; how do you avoid claiming a benefit you are not actually delivering?
2. 2. High-volume HDF needs good access, ultrapure water, and infrastructure — how should that shape who, in the real world, actually receives it?
3. 3. The temptation is to read ‘HDF’ on the prescription and stop thinking; what would make you check the achieved convection volume every time?
4. 4. Middle molecules accumulate silently for years before the carpal tunnel appears; how does an invisible, slow harm earn attention against today's urgent problems?
5. 5. When only high-flux HD is possible, how do you offer it honestly — as the best available, not as the thing the trials studied?

Nine items, each anchored in this chapter. At least one per objective.